Previous 10 | Next 10 |
Invitae Appointed to National Quality Forum Committee on Quality Standards for Healthcare PR Newswire – First genetics testing company to sit on Forum – – Genetics perspective on committee will accelerate healthcare quality standards aligning wit...
Shares of Invitae Corporation (NYSE: NVTA) sank as much as 25.5% this week, according to data from S&P Global Market Intelligence . Even though the company put out a potentially positive press release, the stock plummeted likely due to a fallout from a recent short squeeze, ...
Summary NVTA's business model remains untested, having spent the past decade building a precarious market position with artificially low pricing strategies. Under its turnaround plan, management cut a third of the workforce, which bodes favorably for Q3 EPS and cash flows and offe...
Summary Invitae is a genetic testing specialist with a suite of products targeting oncology, women's health, and other diseases. NVTA stock traded as high as $55 in January 2021, but today it is worth <$3 per share. Losses of >$750m in 2021 and debt of nearly $2bn are th...
Clinical Practice Guidelines Recommend Genetic Testing of All Patients with Breast Cancer PR Newswire – Invitae study reports universal genetic testing improves outcomes for patients with breast cancer – SAN FRANCISCO , Sept. 22, 202...
Shares of Invitae (NYSE: NVTA) were jumping 6.7% higher as of 10:53 a.m. ET on Wednesday after rising as much as 12.9% earlier in the morning. The medical genetics company didn't announce any news today. On Tuesday, though, Invitae and Praxis Precision Medicines stated in a ...
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing PR Newswire – First use of Ciitizen platform as source of real-world data in regulatory filing – SAN FRANCISCO and BOSTON , Sept. 20, 2022 ...
Leading Clinical Experts Across the U.S. Unite to Support Universal Genetic Testing for all Patients with Cancer PR Newswire – Clinicians agree that evidence supports testing benefits for all – SAN FRANCISCO , Sept. 15, 2022 /PRNewsw...
Shares of Invitae (NYSE: NVTA) , a maker of medical genetic tests, fell 14% on Tuesday. The stock closed at $4.00 on Monday, then opened on Tuesday at $3.70, before falling to a daily low of $3.45 around 11 a.m., then rising to $3.48 at Tuesday's close. The stock is down more ...
Invitae Corporation (NVTA) Morgan Stanley 20th Annual Global Healthcare Conference Call September 13, 2022 08:00 ET Company Participants Ken Knight - Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Presentation ...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...